Friday, August 12, 2022
HomeRoboticsHTEC Sees Elevated Composition of Worthwhile Firms Following Q2 Rebalance

HTEC Sees Elevated Composition of Worthwhile Firms Following Q2 Rebalance


One of the differentiators of ROBO Global’s HTEC index vs. other healthcare indices is that the index undergoes a quarterly rebalance. This frequency enables the index to capitalize on the movement that takes place during each quarter in terms of share gains and losses.

The ROBO Global Investment Committee also utilizes the quarter rebalance periods to add or delete companies from the index. Companies must undergo a rigorous review, through which a score is determined. Those who pass the scoring minimum and fundamental screens are included in the index, and those who fail to meet the minimum criteria are removed.

Amidst the current market sentiment, ROBO’s research analysts placed a particularly stringent focus on the loss-making companies in the Index to ensure they have what takes to weather the current storm, maintain their market position and technological advantages, and are delivering on their internal targets. As a result of our updated scoring this quarter, five companies have received a score downgrade resulting in subsequent removal from the index. Following this rebalance, 76.5% of the companies in the index will have a positive Forward EPS, up from 69.4% prior to the rebalance. Given the magnitude of growth opportunities in healthcare tech, we continue to see very strong potential for multiple expansion opportunities among the remaining companies in the index.

The following five companies have been removed from the index based on reduced HTEC scoring.

  • Cardiovascular Systems, a medical technology company focused on peripheral and coronary artery disease, was downgraded due to being outpaced by competition.

 

  • NeoGenomics, a company that provides genetic testing services, received a score reduction due to a lack of investment in innovation and competition gaining technical advantages. The company has been facing challenges, and recently revoked guidance during a time when comps were meeting and exceeding expectations.

 

  • Tabula Rasa HealthCare, a healthcare data analytics and pharmacy services provider has failed to meet the index minimum market capitalization threshold. The pandemic pressured growth for the company, and it is failing to generate ROI on numerous investments made prior to the pandemic.

 

  • Ping An Healthcare and Technology Co is a China-based telehealth and health marketplace service provider. It received a score reduction and removal from HTEC as the company has shifted its model toward more health insurance services and B2B sales, and is facing a high degree of pressure amidst lockdowns in China, with y/y decline in revenue, and a prolonged path to profitability.

 

  • Alibaba Health, another China-based healthcare e-commerce pharmacy service provider, has been downgraded as it faces decelerating revenue and market share loss, and is being outpaced by competition.



RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments